Menu
Menu
MTAP deletion is rapidly emerging as a clinically actionable biomarker across multiple tumor types, frequently associated with a poor prognosis. While this is driving new therapeutic opportunities, it also exposes a major challenge for precision oncology trials: accurately testing for difficult and novel biomarkers. In Europe, especially, this gap continues to delay clinical trial enrolment and slow therapeutic progress.
In this webinar, we will explore how SOPHiA GENETICS, in partnership with ARC Regulatory, is addressing these challenges by implementing a comprehensive genomic profiling assay to enable biomarker identification and patient enrolment for clinical trials across Europe. By combining SOPHiA GENETICS’ AI-powered technology with ARC Regulatory’s expertise in assay implementation and workflow validation, we accelerate CTA development in instances such as MTAP deletion. Together, we aim to reduce regulatory risk in clinical research programs, shorten timelines for clinical trial recruitment, and broaden clinical trial recruitment in Europe.
Join us to gain insights into the nuances of European clinical trial testing and how robust genomic solutions can advance precision oncology research and ultimately improve patient outcomes.
Speakers:
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
